Physician profile

Thomas Perry

Cleveland, OH

NPI 1275223497

$764.81

in general payments reported to CMS, 2019-2025

4 companies · $765 in 2025

The $765 reported for 2025 was more than what 85% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$596.82
Education$167.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $265.59 2025 Esprit, Supera
Stryker Corporation $182.61 2025 Artix Mt
Bolton Medical INC $167.99 2025 Treo Abdominal Stent-Graft System
Terumo Medical Corporation $148.62 2025 Angio-Seal, Azur Cx Detachable

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Perry

$764.81

in general payments reported 2019-2025

Years
2025
Top company
Abbott Laboratories
Context
The $765 reported for 2025 was more than what 85% of providers received nationally.

https://glasscript.com/doctor/11958697/thomas-perry

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.